详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]Chinese Acad Med Sci, Peking Union Med Coll, Leukemia Diag & Treatment Ctr, State Key Lab Expt Hematol,Inst Hematol,Div Leuke, Tianjin 300020, Peoples R China [2]Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China [3]Sichuan Univ, W China Hosp, Dept Hematol, Chengdu 610064, Peoples R China [4]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Hematol, Wuhan 430074, Peoples R China

出处：

DOI：

ISSN：

关键词： Acute myeloid leukemia FLT3 TKD mutations Prognosis Meta-analysis

摘要：

A meta-analysis was performed to demonstrate the prognostic significance of FLT3-TKD mutations in acute myeloid leukemia (AML). The overall hazard ratio (HR) of FLT3-TKD/FLT3-wild type (WT) for disease-free survival (DFS) was 1.20. The overall HRs for overall survival (OS) of FLT3-TKD to FLT3-ITD and FLT3-WT were 0.87 and 1.18. For non-promyelocytic AML with intermediate cytogenetics, the overall HR for DFS of FLT3-TKD/FLT3-ITD was 0.71. The HR for OS of FLT3-TKD/FLT3-ITD was 0.75. Adult AML patients with FLT3-TKD mutations exhibit better outcomes than those with FLT3-ITD. The patients with FLT3-TKD mutations with intermediate cytogenetics had similar OS as those with FLT-WT mutations. (C) 2011 Elsevier Ltd. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2011]版：

大类 | 3 区医学

小类 | 4 区血液学 4 区肿瘤学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区血液学 4 区肿瘤学

JCR分区：

出版当年[2010]版：

Q2 ONCOLOGY Q3 HEMATOLOGY

最新[2024]版：

Q3 HEMATOLOGY Q3 ONCOLOGY

影响因子： 2.2 最新[2024版] 2.3 最新五年平均 2.555 出版当年[2010版] 2.309 出版当年五年平均 2.358 出版前一年[2009版] 2.923 出版后一年[2011版]

第一作者：

第一作者单位： [2]Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China

通讯作者：

通讯机构： [1]Chinese Acad Med Sci, Peking Union Med Coll, Leukemia Diag & Treatment Ctr, State Key Lab Expt Hematol,Inst Hematol,Div Leuke, Tianjin 300020, Peoples R China [2]Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China [*1]Chinese Acad Med Sci, Peking Union Med Coll, Leukemia Diag & Treatment Ctr, State Key Lab Expt Hematol,Inst Hematol,Div Leuke, 288 Nanjing Rd, Tianjin 300020, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia [2]Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia [3]Synergy between FLT3-ITD and p53 Haploinsufficiency or Loss in the Development of Acute Myeloid Leukemia [4]Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis [5]FLT3-ITD-associated gene-expression signatures in NPM1-mutated cytogenetically normal acute myeloid leukemia [6]Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia:Updated Results from a Phase I Study [7]A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation [8]A Novel Defined Pyroptosis-Related Gene Signature for the Prognosis of Acute Myeloid Leukemia [9]A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation. [10]Homoharringtonine combined with the Heat Shock Protein 90 Inhibitor IPI504 in the Treatment of FLT3-ITD Acute Myeloid Leukemia